iBio (IBIO) Depreciation & Amortization (CF) (2010 - 2026)
iBio (IBIO) posted quarterly Depreciation & Amortization (CF) of $147000.0 for Q1 2026, up 21.49% year-over-year from $121000.0 in Q1 2025, and up 4.26% quarter-over-quarter from $141000.0 in Q4 2025.
iBio (IBIO) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $147000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 21.49% year-over-year to $147000.0; the TTM figure through Mar 2026 stood at $532000.0 (up 4.52% YoY), while the FY2025 annual figure was $484000.0, down 24.14% from the prior year.
- Depreciation & Amortization (CF) improved to $147000.0 in Q1 2026 per IBIO's latest filing, from $141000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $743000.0 in Q2 2022 and bottomed at $120000.0 in Q3 2024.
- Historically, Depreciation & Amortization (CF) has averaged $237923.1 across 5 years, with a median of $146000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 495.8% — and 2023, when it slumped 39.11%.
- iBio's Depreciation & Amortization (CF) stood at $271000.0 in 2022, then sank by 39.48% to $164000.0 in 2023, then fell by 25.61% to $122000.0 in 2024, then rose by 15.57% to $141000.0 in 2025, then rose by 4.26% to $147000.0 in 2026.
- Business Quant data shows IBIO's Depreciation & Amortization (CF) at $147000.0 in Q1 2026, $141000.0 in Q4 2025, and $123000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 147,000.00 |
| Mar 31, 2026 | 147,000.00 |
| Dec 31, 2025 | 141,000.00 |
| Dec 31, 2025 | 141,000.00 |
| Sep 30, 2025 | 123,000.00 |
| Sep 30, 2025 | 123,000.00 |
| Jun 30, 2025 | 121,000.00 |
| Jun 30, 2025 | 121,000.00 |
| Mar 31, 2025 | 121,000.00 |
| Mar 31, 2025 | 121,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Dec 31, 2024 | 122,000.00 |
| Sep 30, 2024 | 120,000.00 |
| Sep 30, 2024 | 120,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Jun 30, 2024 | 146,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Dec 31, 2023 | 164,000.00 |
| Sep 30, 2023 | 165,000.00 |
| Sep 30, 2023 | 165,000.00 |